XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

Jenkins, KA; Park, M; Pederzoli-Ribeil, M; Eskiocak, U; Johnson, P; Guzman, W; Mclaughlin, M; Moore-Lai, D; O'Toole, C; Liu, Z; Nicholson, B; Flesch, V; Qiu, HW; Clackson, T; O'Hagan, RC; Rodeck, U; Karow, M; O'Neil, J; Williams, JC

Jenkins, KA (通讯作者)，Xilio Therapeut, Waltham, MA 02451 USA.

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023; 11 (12):

Abstract

IntroductionThe clinical benefit of the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab has been well established but limited by immune-related adver......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索